La Jolla Pharmaceutical Company And The George Washington University Enter Into Agreement For Technology Related To LJPC-501

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that it has signed an option agreement with the George Washington University (“GW”) that will add proprietary technology to the Company’s LJPC-501 program.

Help employers find you! Check out all the jobs and post your resume.